Abeona Therapeutics
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 84
- Market Cap
- $242.5M
- Introduction
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.
EB-101 Treatment for New and Previously Treated Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)
- Conditions
- Epidermolysis BullosaRDEBRecessive Dystrophic Epidermolysis Bullosa
- Interventions
- Biological: EB-101 Surgical application of RDEB wounds
- First Posted Date
- 2023-02-13
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Abeona Therapeutics, Inc
- Target Recruit Count
- 12
- Registration Number
- NCT05725018
- Locations
- 🇺🇸
Stanford University, Redwood City, California, United States
🇺🇸University of Massachusetts Medical School, Worcester, Massachusetts, United States
A Long-Term Extension Study for Participants Previously Treated With EB-101 for the Treatment of RDEB
- Conditions
- RDEB
- Interventions
- Biological: EB-101
- First Posted Date
- 2023-02-01
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Abeona Therapeutics, Inc
- Target Recruit Count
- 22
- Registration Number
- NCT05708677
- Locations
- 🇺🇸
Stanford University, Redwood City, California, United States
🇺🇸University of Massachusetts Medical School, Worcester, Massachusetts, United States
A Long-term Follow-up Study of Patients With MPS IIIB Treated With ABO-101
- Conditions
- Mucopolysaccharidosis III-B
- Interventions
- Biological: ABO-101
- First Posted Date
- 2020-12-07
- Last Posted Date
- 2022-05-31
- Lead Sponsor
- Abeona Therapeutics, Inc
- Target Recruit Count
- 1
- Registration Number
- NCT04655911
- Locations
- 🇫🇷
Armand-Trousseau Hospital, Paris, France
🇩🇪University Hospital Hamburg-Eppendorf, Hamburg, Germany
🇺🇸Nationwide Children's Hospital, Columbus, Ohio, United States
Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
- Conditions
- Recessive Dystrophic Epidermolysis BullosaEpidermolysis Bullosa
- Interventions
- Biological: EB-101
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2022-12-05
- Lead Sponsor
- Abeona Therapeutics, Inc
- Target Recruit Count
- 11
- Registration Number
- NCT04227106
- Locations
- 🇺🇸
University of Massachusetts Medical School, Worcester, Massachusetts, United States
🇺🇸Stanford University, Redwood City, California, United States
Gene Transfer Clinical Trial for Mucopolysaccharidosis (MPS) IIIB
- Conditions
- Mucopolysaccharidosis Type 3 B
- Interventions
- Biological: rAAV9.CMV.hNAGLU
- First Posted Date
- 2017-10-20
- Last Posted Date
- 2022-05-05
- Lead Sponsor
- Abeona Therapeutics, Inc
- Target Recruit Count
- 11
- Registration Number
- NCT03315182
- Locations
- 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇫🇷Armand-Trousseau Hospital, Paris, France
🇩🇪University Hospital Hamburg-Eppendorf, Hamburg, Germany
Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa
- Conditions
- Epidermolysis Bullosa DystrophicaEpidermolysis Bullosa
- Interventions
- Biological: LZRSE-Col7A1 Engineered Autologous Epidermal Sheets
- First Posted Date
- 2010-12-20
- Last Posted Date
- 2023-08-22
- Lead Sponsor
- Abeona Therapeutics, Inc
- Target Recruit Count
- 12
- Registration Number
- NCT01263379
- Locations
- 🇺🇸
Stanford University, School of Medicine, Dept of Dermatology, Redwood City, California, United States
MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers
- First Posted Date
- 2007-11-26
- Last Posted Date
- 2020-09-03
- Lead Sponsor
- Abeona Therapeutics, Inc
- Target Recruit Count
- 342
- Registration Number
- NCT00563433
- Locations
- 🇺🇸
Seattle VA Medical Center, Seattle, Washington, United States
MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers
- First Posted Date
- 2007-11-26
- Last Posted Date
- 2020-09-03
- Lead Sponsor
- Abeona Therapeutics, Inc
- Target Recruit Count
- 584
- Registration Number
- NCT00563394
- Locations
- 🇺🇸
Seattle VA Medical Center, Seattle, Washington, United States
A Trial of the Safety and Efficacy of EcoNailâ„¢ in the Treatment of Fungus Infections of the Great Toenail
- Conditions
- Onychomycosis
- Interventions
- Drug: EcoNail™ (econazole 5%/SEPA® 18% nail lacquer)
- First Posted Date
- 2006-10-09
- Last Posted Date
- 2020-09-03
- Lead Sponsor
- Abeona Therapeutics, Inc
- Target Recruit Count
- 40
- Registration Number
- NCT00385502